A B S T R A C T We recently presented data showing that mannose-6-phosphate was a potent competitive inhibitor of pinocytosis of human platelet f8-glucuronidase, and that treatment of "high-uptake" forms of the enzyme with alkaline phosphatase destroyed the high-uptake property of the enzyme without diminishing its catalytic activity. These data indicate that phosphate is a necessary component of the recognition marker on the enzyme for pinocytosis by human fibroblasts, and suggest that the phosphate on highuptake forms of the enzyme is present as a phosphohexosyl moiety. Results presented here show that mannose-6-phosphate is also a potent inhibitor of pinocytosis of the following enzyme preparations: (a)
INTRODUCTION
Uptake of lysosomal enzymes by fibroblasts, originally recognized as uptake of corrective factors by enzyme-deficient fibroblasts (1) , displays the selectivity and saturability expected for a receptor-mediated process (2) . Selectivity for,f3-glucuronidase uptake was evident from the fact that only certain relatively acidic forms of the enzyme, called "high-uptake" forms, were taken up at rates that greatly exceeded the rate of nonspecific, fluid-or bulk-phase endocytosis (3) (4) (5) (6) . Saturability has been demonstrated with several high-uptake enzymes (6) (7) (8) (9) . We recently reported evidence that high-uptake ,8-glucuronidase from human platelets is a phosphoglycoprotein, and that phosphohexose is an essential component of the recognition marker on the enzyme for the fibroblast pinocytosis receptor (6) .
The phosphohexose on the enzyme has not yet been demonstrated directly. The evidence that phosphate is present on the enzyme and is essential for uptake by fibroblasts was provided by the discovery that alkaline phosphatase treatment of high-uptake enzyme destroyed its uptake activity without diminishing its catalytic activity. This treatment also converted the enzyme to less acidic forms. The suggestion that a phosphate monoester on the high-uptake enzyme is linked to a D-mannose-type sugar was based on the finding that D-mannose-6-phosphate was a potent competitive inhibitor of 8-glucuronidase pinocytosis, in fact, a 1,000-fold more potent inhibitor than D-mannose.
In addition, phosphomannose-containing yeast mannans were also potent competitive inhibitors of 8-glucuronidase pinocytosis.
Here we present evidence that phosphohexosyl recognition is not limited to pinocytosis of B-glucuronidase from platelets. Phosphohexosyl recognition is shown to be involved in pinocytosis of, 8 (11) . The /3-hexosaminidase was eluted with the citrate buffer containing 0.1 Ml N-acetylglucosamine and 0.1 mg/ml human serum albumin, concentrated by ultrafiltration, and dialyzed against 0.01 M Tris-HCl, pH 7.6, 0.075 M NaCl. /3-Galactosidase was prepared from platelet lysates (6) by affinity chromatography on Sepharose 4B-amino-hexyl-l-thio-,B-D-galactopyranoside as described by Miller et al. (12) , except that the enzyme was applied and eluted in 0.01 NI sodium acetate, pH 4.4.
Assaiys. Fluorometric enzyme assays measured release of 4-methyl-umbelliferone from the appropriate glycoside (13) . Synthetic substrate concentrations were 10 mM in 0.1 M sodium acetate, pH 4.8, for /3-glucuronidase; 5 mNI in 0.02 M sodium phosphate-citrate, pH 4.4, for, 3-hexos-aminidase; and 1 mM in 0.08 M sodium phosphate-citrate, pH 4.4, for /8-galactosidase. In all of the assays, 25 Al of enzyme was added to 100 ,ul of substrate and then the mixture was incubated at 37°C. Reactions were stopped by the addition of 1.8 ml of glycine-carbonate buffer, pH 10.3 (13) . 1 U of activity is the amount of enzyme which catalyzes the release of 1 nmol of 4-methylumbelliferone/hr. Protein was measured according to Lowry et al. (14) . Pinocytosis of enzymes by fibroblasts was measured as previously described (6). The conditions for pinocytosis rate measurements are given in the legend to Table I .
RESULTS
We previously reported different rates of pinocytosis by human fibroblasts for /8-glucuronidase prepared from different human tissue sources (3) . The pinocytosis rate correlated with the relative amount of acidic high-uptake forms in the enzyme preparations (4). Table I compares the pinocytosis of human /8- glucuronidase from different sources and the effect of maininose-6-phosphate on the pinocytosis rate. Platelet and spleen enzyme are much richer in high-uptake formns than enzyme from liver, placenta, or urine, as previously reported (3) (4) (5) (6) . However, even the enzyme with the lowest pinocytosis rate (urinary enzyme) is taken up in the absence of mannose-6-phosphate at a rate that is one to two orders of magnitude greater than the rate of nonspecific fluid endocytosis. The most important point from Table I is that despite differences in the amount of high-uptake enzyme in 1-glucuronidase from different sources, mannose-6-phosphate dramatically inhibits the pinoeytosis of the enzyme from every source tested. We also reported previously (6) that the pinocytosis of human platelet ,3-glucuronidase was greatly diminished by alkaline phosphatase treatment of the enzyme. Table   I , and the pinocytosis rates for these 13-glucuronidase preparations were measured as described in Methods. The specific activitx of the alkaline phosphatase wvas 25 ,uM/mg per min Pi release. platelet enzyme. Evidence that the alkaline phosphatase treatment of platelet 83-glucuronidase reduces the amount of cell-associated enzyme by destroying the uptake property, rather than rendering the enzyme more sensitive to inactivation following uptake, was provided by the following experiment. When 2,000 U of either untreated or alkaline phosphatase-treated platelet 13-glueuronidase was incubated with cells for 15 h, over 98% of the added 8-glucuronidase activity was recovered as the sum of the cell-associated activity plus that remaining in the medium, even though 28% of the untreated enzyme and only 4.8% of the alkaline phosphatase-treated enzyme had been taken up. Thus, the alkaline phosphatase-treated enzyme that did not appear in the cells was still present in the medium. The data in Table II on 13- glucuronidase from other sources indicate that alkaline phosphatase treatment also greatly reduces the susceptibilit) to pinocytosis (destroys the high-uptake property) of 83-glucuronidase from spleeln, liver, placenta, and urine. Thus, 13-glucuronidase from these sources appears to have a similar recognition marker to that of enzyme from platelets. We next compared the effect of mannose-6-phosphate and other hexose phosphates on pinocytosis of other lysosomal hydrolases to their effect on platelet ,f-glucuronidase. Table III presents data on the inhibition of pinocytosis of several lysosomal hydrolases by mannose-6-phosphate. The striking inhibition of enzyme pinocytosis by mannose-6-phosphate is evident, not only for 13-glucuronidase from platelets as previ-ously reported (6), but also for 8-galactosidase and ,8-hexosaminidase from platelet extracts, and for 8-hexosaminidase from fibroblast secretions. Fig. 1 summarizes data comparing several hexose phosphates as inhibitors of pinocytosis of four different hydrolase preparations. In every case, mannose-6-phosphate was the most potent inhibitor of enzyme pinocytosis. The patterns of inhibition of pinocytosis were similar to each other and similar to that previously reported for platelet /-glucuronidase (6) . Table IV demonstrates the sensitivity of the highuptake property of/8-hexosaminidase to prior treatment of the enzyme with alkaline phosphatase. I.--i-P 2-DEOXY-MAN-I-P GAL-6-P GLC-6-P INHIBITOR (0.5 mM) FIGURE 1 Inhibition of enzyme pinocytosis by different sugar phosphates. The enzymes were prepared as described in Methods. Pinocytosis was measured as in Tables I and II in the presence and absence of the indicated hexose phosphates. ,8-Glucuronidase-deficient fibroblasts were used as acceptor cells for /3-glucuronidase, Sandhoff's disease fibroblasts for /3-hexosaminidase, and I-cell disease fibroblasts for /8-galactosidase. The enzyme concentration used and the pinocytosis rate for each enzyme in the absence of inhibitors were: /8-glucuronidase (platelet) 2,000 U/ml, 162 U/mg per h; /3-galactosidase (platelet) 3,600 U/ml, 58 U/mg per h; 3-hexosaminidase (platelet) 10,000 U/ml, 69 U/mg per h; and f3-hexosaminidase (fibroblast) 1,400 U/ml, 162 U/mg per h. these data one could not exclude the possibility that the phosphohexosyl recognition component is limited to blood platelet enzymes. Small amounts of high-uptake enzymes in other organs could be due to the presence of blood platelets in these organs. However, the high-uptake fibroblast secretion enzyme cannot be attributed to blood platelets. High-uptake enzyme was found to be a substantial fraction of the 3-hexosaminidase secreted by cultured fibroblasts for at least 4 wk after transfer from serum-containing to serum-free medium.' The high-uptake f3-hexosaminidase from fibroblast secretions had the same properties as high-uptake /3-hexosaminidase from platelets and as high-uptake /3-glucuronidase from all sources tested. Additionally, although the data have not yet been published, Neufeld et al. (9) recently reported that high-uptake human a-L-iduronidase from urine was similar to human platelet f8-glucuronidase (6) in the sensitivity of its uptake to inhibition by mannose-6-phosphate, and in the susceptibility of its uptake activity to inactivation by alkaline phosphatase.
Hickman and Neufeld (10) originally proposed that lysosomal enzymes have a "common recognition marker" for uptake and suggested that this recognition marker was defective or masked on lysosomal enzymes from I-cell disease fibroblasts. Carbohydrate in the recognition marker was suggested by the finding that the uptake activity of /8-hexosaminidase was inactivated by treatment of the enzyme with periodate (15). tfieber et al. (7) recently suggested glycosidically bound mannose in the recognition marker on /-galactosidase from beef testes, but concluded that uptake of this enzyme was mediated by a different system than that responsible for /3-glucuronidase uptake. Our recent studies (6) implicated phosphate in the recognition marker on high-uptake human platelet p-glucuronidase and suggested that the phosphate was present as a phosphomannosyl moiety on the enzyme. The present report supports the generality of a phosphohexose-type recognition marker on human lysosomal enzymes and suggests that phosphomannose is an essential part ofthe previously suggested common recognition marker.
The findings implicating phosphohexose on lysosomal enzymes were unexpected. Until 
